Denali Therapeutics Inc. (DNLI)
Denali Therapeutics Inc. (DNLI) is a healthcare company (biotechnology) based in the United States. The share price is $17.93, down 0.83% on the day, which values the company at $2.87B. Price as of 17 Nov 2026, 17:28 UTC, from Yahoo Finance.
Key facts
- Share price
- $17.93−0.83% today
- Market value
- $2.87B
- 200-week average
- $20.9014% below
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Denali Therapeutics Inc. in more detail
DNLI trades at -7.9× next year's expected earnings, 134.4× sales. It sits 14% below its 200-week average of $20.90.
In its favour: More cash than debt. Worth checking: Weak Piotroski score; Share count keeps rising.
4 of the superinvestors tracked here hold DNLI, including Julian and Felix Baker (0.5% of the portfolio), Temasek (0.4% of the portfolio), Brandon Haley (0.2% of the portfolio).
Superinvestors holding DNLI
4 of the investors tracked here report a position in their latest 13F filing.
- Julian and Felix Baker Baker Bros. Advisors0.48% of portfolio · $96M · added · Q2 2026
- Temasek Temasek Holdings0.40% of portfolio · $145M · Q3 2026
- Brandon Haley Holocene Advisors0.23% of portfolio · $100.4M · added · Q2 2026
- Baillie Gifford team Baillie Gifford & Co0.22% of portfolio · $229.8M · trimmed · Q3 2026
Denali Therapeutics Inc. (DNLI): questions and answers
What is Denali Therapeutics Inc.'s market cap?
Denali Therapeutics Inc. is valued at $2.87B at a share price of $17.93.
Is DNLI above its 200-week moving average?
No. DNLI is 14.2% below its 200-week average of $20.90. Long-term investors watch that line because strong companies rarely trade below it for long.
Does DNLI pay a dividend?
Denali Therapeutics Inc. does not currently pay a regular dividend.
Which famous investors own DNLI?
In their latest quarterly filings, Julian and Felix Baker (0.5% of the portfolio), Temasek (0.4% of the portfolio), Brandon Haley (0.2% of the portfolio), Baillie Gifford team (0.2% of the portfolio) hold DNLI. These filings are published up to 45 days after each quarter ends, so positions may have changed since.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Denali Therapeutics Inc. (DNLI) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/DNLI
Underlying data: Yahoo Finance; company filings with the SEC.